Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30792317 | 1.00 | CYP3A4 (0.58) | CYP3A4MAPK1USP2SMN1; SMN2POLB | |
| SCHEMBL26481061 | 0.92 | CYP3A4 (0.71) | CYP3A4MAPK1USP2SMN1; SMN2POLB | |
| SCHEMBL30350587 | 0.92 | CYP3A4 (0.71) | CYP3A4MAPK1USP2SMN1; SMN2POLB | |
| SCHEMBL4133119 | 0.90 | CYP3A4 (0.43) | CYP3A4MAPK1USP2SMN1; SMN2POLB | |
| SCHEMBL7893039 | 0.90 | CYP3A4 (0.55) | CYP3A4MAPK1USP2SMN1; SMN2POLB | |
| SCHEMBL29928265 | 0.87 | CYP3A4 (0.49) | CYP3A4MAPK1USP2SMN1; SMN2POLB | |
| SCHEMBL657376 | 0.87 | CYP3A4 (0.51) | CYP3A4MAPK1USP2SMN1; SMN2POLB | |
| SCHEMBL18526952 | 0.86 | MAOB (0.51) | CYP3A4MAPK1USP2SMN1; SMN2MAPT | |
| SCHEMBL12375248 | 0.85 | CYP3A4 (0.51) | CYP3A4MAPK1USP2SMN1; SMN2MAPT | |
| SCHEMBL28321480 | 0.84 | CYP3A4 (0.50) | CYP3A4MAPK1USP2SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221944-A1 | COMPOSITION FOR PREVENTING OR TREATING MULTIPLE MYELOMA COMPRISING NOVEL CHROMANON COMPOUND AS ACTIVE INGREDIENT | KBLUEBIO INC (KR) | 2025-07-10 | — | — | US | disclosed |
| EP-4556004-A1 | HOP DERIVED COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES CAUSED BY CORONAVIRUSES | Centre National de la Recherche Scientifique (FR) | 2025-05-21 | — | — | EP | disclosed |
| US-20250134146-A1 | FLAVANONE COMPOUNDS AND THEIR USE AS FLAVOR MODIFIERS | FIRMENICH INCORPORATED (US) | 2025-05-01 | — | — | US | disclosed |
| EP-4506328-A1 | COMPOSITION FOR PREVENTING OR TREATING MULTIPLE MYELOMA COMPRISING NOVEL CHROMANON COMPOUND AS ACTIVE INGREDIENT | KBlueBio Inc (KR) | 2025-02-12 | — | — | EP | disclosed |
| EP-2984072-B1 | SYNTHETIC ANALOGUES OF XANTHOHUMOL | UNIV PISA (IT) | 2024-05-29 | — | — | EP | disclosed |
| CN-117534661-A | Methyl ophiopogon flavone A derivative and preparation and application thereof | 中国医学科学院药物研究所 | 2024-02-09 | — | — | CN | disclosed |
| WO-2024027521-A1 | METHYLOPHIOPOGONONE A DERIVATIVE, AND PREPARATION AND USE THEREOF | 中国医学科学院药物研究所 | 2024-02-08 | — | — | WO | disclosed |
| WO-2023195791-A1 | COMPOSITION FOR PREVENTING OR TREATING MULTIPLE MYELOMA COMPRISING NOVEL CHROMANON COMPOUND AS ACTIVE INGREDIENT | 케이블루바이오 주식회사 | 2023-10-12 | — | — | WO | disclosed |
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2023-05-09 | — | — | US | disclosed |
| WO-2021068533-A1 | DRUG FOR ANTAGONIZING REPLICATION OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND APPLICATION THEREOF | 南京农业大学 | 2021-04-15 | — | — | WO | disclosed |
| EP-1980248-A1 | Composition for treating cancer cells and synthetic method for the same | Kaohsiung Medical University (TW) | 2008-10-15 | — | — | EP | disclosed |
| EP-1957474-A1 | SYNTHESIS OF INHIBITORS OF FTSZ | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007056188-A1 | SYNTHESIS OF INHIBITORS OF FTSZ | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2001007034-A1 | MULTIDRUG RESISTANCE PUMP INHIBITORS AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2001-02-01 | — | — | WO | disclosed |
| US-5521216-A | TREATING COMPLICATIONS OF DIABETES | TSUMURA & CO. (JP) | 1996-05-28 | — | — | US | disclosed |
| US-5455267-A | For reducing side effects of diabetes | TSUMURA & CO. (JP) | 1995-10-03 | — | — | US | disclosed |
| EP-0605728-A1 | CHROMONE DERIVATIVE AND ALDOSE REDUCTASE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | TSUMURA & CO. (JP) | 1994-07-13 | — | — | EP | disclosed |
| US-5234951-A | Anti-ulcer agent comprising chalcone derivative | TSUMURA JUNTENDO, INC. (JP) | 1993-08-10 | — | — | US | disclosed |
| US-5106871-A | Reduced side effects | TSUMURA & CO. (JP) | 1992-04-21 | — | — | US | disclosed |
| EP-0292576-A1 | ANTI-ULCEROUS AGENT CONTAINING CHALCONE DERIVATIVE AS EFFECTIVE INGREDIENT AND NOVEL CHALCONE DERIVATIVES | TSUMURA & CO. (JP) | 1988-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643405-B2 | Compound for treatment or prevention of liver diseases | SLC10A1, GYS2, CPT1A | CYP3A4 187/4885MAPK1 2177/4885USP2 4095/4885 |
| US-20250221944-A1 | COMPOSITION FOR PREVENTING OR TREATING MULTIPLE MYELOMA COMPRISING NOVEL CHROMANON COMPOUND AS ACTIVE INGREDIENT | MCL1, CRBN, BCL3 | CYP3A4 2304/4885MAPK1 688/4885USP2 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.